ReviewBlood2015
Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.
Review in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it, 233 citations in OpenAlex.
- The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.Nature reviews. Nephrology · 2019Guideline
- Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017.Acta clinica Croatica · 2018Guideline
- Trial
- Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.Haematologica · 2018Trial
- C3 Glomerulopathy With Occult Gammopathy Treated With Low-Dose, Fixed Duration Venetoclax.Kidney international reports · 2026Article
- Lymphocyte count and risk of chronic lymphocytic leukemia.Journal of the National Cancer Institute · 2026Article
- Single-cell analysis of the human immune system reveals sex-specific dynamics of immunosenescence.Nature aging · 2026Article
- Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy.Clinical and translational medicine · 2026Review
- Beyond CKD-Associated Pruritus: Paraneoplastic Itch Revealing CLL/SLL in ESRD: A Case Report.The American journal of case reports · 2025Article
- Mixed Cryoglobulinemia in the Setting of Monoclonal B-Cell Lymphocytosis and Monoclonal Gammopathy of Unknown Significance: A Case Report.The American journal of case reports · 2025Article
- Incidental Detection of Neoplastic B Cells in the Colon Following Resection in a Patient With Adenocarcinoma.ACG case reports journal · 2025Article
- A Single-Center Retrospective Study of the Investigation of Monoclonal B-Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL) in Southwestern Ontario: Are We Over-Investigating?International journal of laboratory hematology · 2025Article
- Macular retinoschisis in a patient with multiple lymphoproliferative malignancies.American journal of ophthalmology case reports · 2025Article
- Expansion of multiple CD4The Journal of allergy and clinical immunology · 2025Article
- Chronic lymphocytic leukemia often arises by a multiclonal selection process.Haematologica · 2025Article
- A case of renal damage induced by cryoglobulinemia associated with Monoclonal Gammopathy of Renal Significance.BMC nephrology · 2025Article
- Machine Learning Model Predicts Abnormal Lymphocytosis Associated With Chronic Lymphocytic Leukemia.JCO clinical cancer informatics · 2025Observational
- Successful Treatment of Monoclonal Immunotactoid Glomerulopathy Associated with Chronic Lymphocytic Leukemia Using Ibrutinib.Internal medicine (Tokyo, Japan) · 2025Article
- Donor Cell-Derived Chronic Lymphocytic Leukemia Presenting After Allogenic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.Journal of hematology · 2025Article
- Improving outcome prediction in indolent ATL by subdividing intermediate risk into low- and high-intermediate groups.Annals of hematology · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal B lymphocytosis (MBL) is defined as the presence of a clonal B-cell population in the peripheral blood with fewer than 5 × 10(9)/L B-cells and no other signs of a lymphoproliferative disorder. The majority of cases of MBL have the immunophenotype of chronic lymphocytic leukemia (CLL). MBL can be categorized as either low count or high count based on whether the B-cell count is above or below 0.5 × 10(9)/L. Low-count MBL can be detected in ∼5% of adults over the age of 40 years when assessed using standard-sensitivity flow cytometry assays. A number of biological and genetic characteristics distinguish low-count from high-count MBL. Whereas low-count MBL rarely progresses to CLL, high-count MBL progresses to CLL requiring therapy at a rate of 1% to 2% per year. High-count MBL is distinguished from Rai 0 CLL based on whether the B-cell count is above or below 5 × 10(9)/L. Although individuals with both high-count MBL and CLL Rai stage 0 are at increased risk of infections and second cancers, the risk of progression requiring treatment and the potential to shorten life expectancy are greater for CLL. This review highlights challenging questions regarding the classification, risk stratification, management, and supportive care of patients with MBL and CLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.